Shots:
- The IIT P-II (IPAX-Linz) trial assessed TLX101 (IV) in 8 glioblastoma pts with recurrent tumors & PET-confirmed amino acid uptake, who received adaptive dosing with ~4GBq before & ~2GBq after, 2L EBRT; 5/8 had MGMT-unmethylated tumors
- Trial showed mOS of 12.4mos. or 32.2mos. from initial diagnosis, complementing P-I (IPAX-1) trial results of 13mos. & 23mos., respectively, vs 9.9mos for EBRT alone; data to be presented at NMN 2025
- TLX101 is being evaluated in P-I/II (IPAX-2) trial with SoC for 1L glioblastoma (recruitment ongoing). Also, Telix plans to start trial for recurrent glioblastoma in Australia in H2’25, pending ethics approval, with US trials to follow in H2’25 pending IND filing in H1’25
Ref: Prnewswire | Image: Telix Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
